Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $29.00 price target on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Performance

Shares of NASDAQ:IMNN traded up $0.00 during midday trading on Thursday, reaching $0.81. The company had a trading volume of 184,772 shares, compared to its average volume of 163,790. Imunon has a 1-year low of $0.64 and a 1-year high of $3.65. The firm has a market cap of $11.69 million, a price-to-earnings ratio of -0.43 and a beta of 2.03. The company has a fifty day simple moving average of $0.89 and a two-hundred day simple moving average of $0.95.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.13. Analysts expect that Imunon will post -1.68 EPS for the current year.

Institutional Investors Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC increased its holdings in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the period. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.